Drugs / CHF6366
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03378648 | Dec 2017 → Apr 2019 | asthma, chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHF6366 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03378648 ↗ |
| Route | Inhaled | “after inhalation dosing” NCT03378648 ↗ |